Skip to content
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Menu
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Publications
All our publications
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Porta C, et al.
Minerva Urol Nephrol.
2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
Monteiro FSM, et al.
Clin Genitourin Cancer.
2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Massari F, et al.
Eur Urol Oncol.
2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Fiala O, et al.
Target Oncol.
2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Incorvaia L, et al.
Cancer Immunol Immunother.
2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).
Ciccarese C, et al.
Int J Cancer.
2024
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
